You are here

  • Home
  • Archive
  • Volume 107, Issue 1
  • Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema

Article metrics

Article menu

Download PDFPDF

Clinical science
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema

 

Online download statistics by month:

Online download statistics by month: August 2021 to March 2024

AbstractFullPdf
Aug 2021197419711523
Sep 2021175417521443
Oct 202113813425
Nov 202113712832
Dec 202114213974
Jan 202210911230
Feb 202210911115
Mar 202215415216
Apr 202217217217
May 202215015014
Jun 202223122819
Jul 202217016925
Aug 202245945917
Sep 202214113917
Oct 202213113122
Nov 202217117015
Dec 202259359788
Jan 2023500498155
Feb 202332733179
Mar 202339038740
Apr 202334334129
May 202325325338
Jun 202321421019
Jul 2023868620
Aug 202366656
Sep 2023979419
Oct 2023777714
Nov 2023858213
Dec 2023494820
Jan 2024383724
Feb 2024313314
Mar 2024444351
Total933592993933